Beacon Financial Group Decreases Position in Sanofi (NASDAQ:SNY)

Beacon Financial Group decreased its holdings in shares of Sanofi (NASDAQ:SNY) by 7.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 14,176 shares of the company’s stock after selling 1,133 shares during the quarter. Beacon Financial Group’s holdings in Sanofi were worth $684,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Portfolio Design Labs LLC acquired a new position in Sanofi during the fourth quarter worth approximately $205,000. Savant Capital LLC increased its position in Sanofi by 24.8% during the fourth quarter. Savant Capital LLC now owns 6,361 shares of the company’s stock worth $307,000 after buying an additional 1,264 shares during the period. Apollon Wealth Management LLC increased its holdings in shares of Sanofi by 8.8% in the fourth quarter. Apollon Wealth Management LLC now owns 17,865 shares of the company’s stock valued at $862,000 after purchasing an additional 1,441 shares during the period. Mezzasalma Advisors LLC increased its holdings in shares of Sanofi by 24.0% in the fourth quarter. Mezzasalma Advisors LLC now owns 12,686 shares of the company’s stock valued at $612,000 after purchasing an additional 2,452 shares during the period. Finally, Strategic Financial Concepts LLC acquired a new position in shares of Sanofi in the fourth quarter valued at approximately $667,000. Hedge funds and other institutional investors own 14.04% of the company’s stock.

Sanofi Stock Up 1.2 %

SNY opened at $54.56 on Thursday. The business’s fifty day moving average is $50.07 and its two-hundred day moving average is $52.41. The company has a debt-to-equity ratio of 0.15, a quick ratio of 0.74 and a current ratio of 1.46. The company has a market cap of $138.46 billion, a price-to-earnings ratio of 21.91, a PEG ratio of 0.99 and a beta of 0.57. Sanofi has a one year low of $45.22 and a one year high of $58.97.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings data on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.70. Sanofi had a return on equity of 25.58% and a net margin of 12.77%. Analysts anticipate that Sanofi will post 4.36 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on SNY shares. StockNews.com lowered Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Sanford C. Bernstein raised Sanofi to a “strong-buy” rating in a report on Thursday, January 30th. Finally, Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. Two equities research analysts have rated the stock with a hold rating, one has issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $60.00.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.